Anastrozole Tablet
Product Images NDC 69117-0003

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 69117-0003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Yiling Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000 Tablets (1000)

Packaging label for Anastrozole Tablets, USP 1 mg oral tablets by Yiling Pharmaceutical, Inc. The label shows a package size of 1000 tablets and includes manufacturer information for Beijing Yiling Bio-engineering Technology Co., Ltd. in Beijing, China, and distributor details in Las Vegas, NV, USA. It also displays a barcode and dosage storage instructions.*

FDA Label Image

30 Tablets (30)

Anastrozole Tablets, USP 1 mg oral tablets by Yiling Pharmaceutical, Inc. The label includes dosage strength, usage warnings, storage instructions, manufacturer details (Beijing Yiling Bio-engineering Technology Co., Ltd., China), distributor address (Las Vegas, NV, USA), and a quantity of 30 tablets. The product is Rx only.*

FDA Label Image

7b4ba0c5 0287 B7a7 E053 2991aa0a575e

Anastrozole 1 mg oral tablets shown as two round white tablets imprinted with "YL" on one side and "111" on the other side, manufactured by Yiling Pharmaceutical, Inc.*

FDA Label Image

Chemical Structure For Anastrozole (Image 01)

Chemical structure of anastrozole showing a benzene ring with two nitrile groups and a triazole ring attached, representing the active ingredient in Anastrozole Tablets 1 mg oral tablets by Yiling Pharmaceutical, Inc.*

FDA Label Image

Figure 1 (Image 02)

A Kaplan-Meier survival curve comparing disease-free survival over time (in months) between two randomized treatments: anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, and the x-axis shows time up to 90 months. A table below the graph lists the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Image 03)

A survival curve graph depicting disease-free survival over time in months for patients treated with anastrozole and tamoxifen. The y-axis shows the proportion of patients alive and disease-free, while the x-axis represents disease-free survival in months, ranging from 0 to 90. Two lines compare treatment groups: a dashed line for anastrozole and a solid line for tamoxifen. Below the graph, the number of patients at risk is listed for each time point for both treatments.*

FDA Label Image

Figure 3 (Image 04)

A Kaplan-Meier survival curve chart depicting the proportion event-free over time (months) for Anastrozole versus Tamoxifen treatments. The x-axis shows time to event in months up to 120, and the y-axis shows proportion event-free from 0.5 to 1.0. Below the graph is a table indicating the number of patients at risk for each treatment group at various time points.*

FDA Label Image

Figure 4 (Image 05)

A Kaplan-Meier survival curve chart comparing the proportion of patients event-free over time (months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to event in months, and the y-axis represents the proportion event-free. The chart includes a table showing the number of patients at risk at various month intervals for both groups, with a note about vertical axis truncation to clarify the curves.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing the proportion not progressing over time (months) for two treatments: Anastrozole tablets and Tamoxifen, showing time to progression. The graph includes a legend identifying the solid line as Anastrozole and the dashed line as Tamoxifen, with corresponding numeric data below representing the number of patients at risk at various time points.*

FDA Label Image

Figure 6 (Image 07)

A Kaplan-Meier plot depicting progression-free survival over time in months, comparing two randomized treatments: Anastrozole and Tamoxifen. The y-axis represents the proportion not experiencing progression, ranging from 0.0 to 1.0, while the x-axis shows time up to 42 months. The graph includes sample sizes at risk for each time point for both treatments.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.